Molecular mechanisms of cisplatin resistance in cervical cancer

Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%–20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Haiyan, Luo, Hui, Zhang, Wenwen, Shen, Zhaojun, Hu, Xiaoli, Zhu, Xueqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907638/
https://www.ncbi.nlm.nih.gov/pubmed/27354763
http://dx.doi.org/10.2147/DDDT.S106412
_version_ 1782437567547834368
author Zhu, Haiyan
Luo, Hui
Zhang, Wenwen
Shen, Zhaojun
Hu, Xiaoli
Zhu, Xueqiong
author_facet Zhu, Haiyan
Luo, Hui
Zhang, Wenwen
Shen, Zhaojun
Hu, Xiaoli
Zhu, Xueqiong
author_sort Zhu, Haiyan
collection PubMed
description Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%–20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer.
format Online
Article
Text
id pubmed-4907638
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49076382016-06-28 Molecular mechanisms of cisplatin resistance in cervical cancer Zhu, Haiyan Luo, Hui Zhang, Wenwen Shen, Zhaojun Hu, Xiaoli Zhu, Xueqiong Drug Des Devel Ther Review Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%–20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer. Dove Medical Press 2016-06-07 /pmc/articles/PMC4907638/ /pubmed/27354763 http://dx.doi.org/10.2147/DDDT.S106412 Text en © 2016 Zhu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zhu, Haiyan
Luo, Hui
Zhang, Wenwen
Shen, Zhaojun
Hu, Xiaoli
Zhu, Xueqiong
Molecular mechanisms of cisplatin resistance in cervical cancer
title Molecular mechanisms of cisplatin resistance in cervical cancer
title_full Molecular mechanisms of cisplatin resistance in cervical cancer
title_fullStr Molecular mechanisms of cisplatin resistance in cervical cancer
title_full_unstemmed Molecular mechanisms of cisplatin resistance in cervical cancer
title_short Molecular mechanisms of cisplatin resistance in cervical cancer
title_sort molecular mechanisms of cisplatin resistance in cervical cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907638/
https://www.ncbi.nlm.nih.gov/pubmed/27354763
http://dx.doi.org/10.2147/DDDT.S106412
work_keys_str_mv AT zhuhaiyan molecularmechanismsofcisplatinresistanceincervicalcancer
AT luohui molecularmechanismsofcisplatinresistanceincervicalcancer
AT zhangwenwen molecularmechanismsofcisplatinresistanceincervicalcancer
AT shenzhaojun molecularmechanismsofcisplatinresistanceincervicalcancer
AT huxiaoli molecularmechanismsofcisplatinresistanceincervicalcancer
AT zhuxueqiong molecularmechanismsofcisplatinresistanceincervicalcancer

Ejemplares similares